Mechanism of action of IL-7 and its potential applications and limitations in cancer immunotherapy

International Journal of Molecular Sciences

Volumn 16, Issue 5, 2015, Pages 10267-10280

  Gao, Jianbao ^a   Zhao, Lintao ^a   Wan, Yisong Y ^b   Zhu, Bo ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Cancer; IL 7; Immunotherapy

Indexed keywords

INTERLEUKIN 7; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TRANSFORMING GROWTH FACTOR BETA;

CANCER IMMUNOTHERAPY; CELL PROLIFERATION; CELL SURVIVAL; DOWN REGULATION; GENE EXPRESSION; HOMEOSTASIS; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE RESPONSE; IMMUNE SYSTEM; LYMPH NODE; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; LYMPHOID ORGAN; ORGANOGENESIS; REVIEW; SIGNAL TRANSDUCTION; TUMOR REGRESSION; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASMS; PROCEDURES; T LYMPHOCYTE;

ANIMALIA;

ANIMALS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-7; NEOPLASMS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84929346696     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms160510267     Document Type: Review

References (79)

1. Puel, A.; Ziegler, S.F.; Buckley, R.H.; Leonard, W.J. Defective IL7R expression in T−B+NK+ severe combined immunodeficiency. Nat. Genet. 1998, 20, 394–397.
2. Surh, C.D.; Sprent, J. Homeostasis of naive and memory T cells. Immunity 2008, 29, 848–862.
3. Kittipatarin, C.; Khaled, A.R. Interlinking interleukin-7. Cytokine 2007, 39, 75–83.
4. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674.
5. ElKassar, N.; Gress, R.E. An overview of IL-7 biology and its use in immunotherapy. J. Immunotoxicol. 2010, 7, 1–7.
6. Lundstrom, W.; Fewkes, N.M.; Mackall, C.L. IL-7 in human health and disease. Semin. Immunol. 2012, 24, 218–224.
7. Mazzucchelli, R.I.; Warming, S.; Lawrence, S.M.; Ishii, M.; Abshari, M.; Washington, A.V.; Feigenbaum, L.; Warner, A.C.; Sims, D.J.; Li, W.Q.; et al. Visualization and identification of IL-7 producing cells in reporter mice. PLoS ONE 2009, 4, e7637.
8. Link, A.; Vogt, T.K.; Favre, S.; Britschgi, M.R.; Acha-Orbea, H.; Hinz, B.; Cyster, J.G.; Luther, S.A. Fibroblastic reticular cells in lymph nodes regulate the homeostasis of naive T cells. Nat. Immunol. 2007, 8, 1255–1265.
9. Onder, L.; Narang, P.; Scandella, E.; Chai, Q.; Iolyeva, M.; Hoorweg, K.; Halin, C.; Richie, E.; Kaye, P.; Westermann, J. et al. IL-7-producing stromal cells are critical for lymph node remodeling. Blood 2012, 120, 4675–4683.
10. Di Carlo, E.; DʼAntuono, T.; Pompa, P.; Giuliani, R.; Rosini, S.; Stuppia, L.; Musiani, P.; Sorrentino, C. The lack of epithelial interleukin-7 and BAFF/BLyS gene expression in prostate cancer as a possible mechanism of tumor escape from immunosurveillance. Clin. Cancer Res. 2009, 15, 2979–2987.
11. Guimond, M.; Veenstra, R.G.; Grindler, D.J.; Zhang, H.; Cui, Y.; Murphy, R.D.; Kim, S.Y.; Na, R.; Hennighausen, L.; Kurtulus, S.; et al. Interleukin 7 signaling in dendritic cells regulates the homeostatic proliferation and niche size of CD4+ T cells. Nat. Immunol. 2009, 10, 149–157.
12. Golden-Mason, L.; Kelly, A.M.; Traynor, O.; McEntee, G.; Kelly, J.; Hegarty, J.E.; OʼFarrelly, C. Expression of interleukin 7 (IL-7) mRNA and protein in the normal adult human liver: Implications for extrathymic T cell development. Cytokine 2001, 14, 143–151.
13. Sawa, Y.; Arima, Y.; Ogura, H.; Kitabayashi, C.; Jiang, J.J.; Fukushima, T.; Kamimura, D.; Hirano, T.; Murakami, M. Hepatic interleukin-7 expression regulates T cell responses. Immunity 2009, 30, 447–457.
14. Jiang, Q.; Li, W.Q.; Aiello, F.B.; Mazzucchelli, R.; Asefa, B.; Khaled, A.R.; Durum, S.K. Cell biology of IL-7, a key lymphotrophin. Cytokine Growth Factor Rev. 2005, 16, 513–533.
15. Kang, J.; Coles, M. IL-7: The global builder of the innate lymphoid network and beyond, one niche at a time. Semin. Immunol. 2012, 24, 190–197.
16. Kerdiles, Y.M.; Beisner, D.R.; Tinoco, R.; Dejean, A.S.; Castrillon, D.H.; DePinho, R.A.; Hedrick, S.M. Foxo1 links homing and survival of naive T cells by regulating l-selectin, CCR7 and interleukin 7 receptor. Nat. Immunol. 2009, 10, 176–184.
17. Ouyang, W.; Beckett, O.; Flavell, R.A.; Li, M.O. An essential role of the forkhead-box transcription factor foxo1 in control of T cell homeostasis and tolerance. Immunity 2009, 30, 358–371.
18. Xue, H.H.; Bollenbacher, J.; Rovella, V.; Tripuraneni, R.; Du, Y.B.; Liu, C.Y.; Williams, A.; McCoy, J.P.; Leonard, W.J. GA binding protein regulates interleukin 7 receptor α-chain gene expression in T cells. Nat. Immunol. 2004, 5, 1036–1044.
19. Park, J.H.; Yu, Q.; Erman, B.; Appelbaum, J.S.; Montoya-Durango, D.; Grimes, H.L.; Singer, A. Suppression of IL7Rα transcription by IL-7 and other prosurvival cytokines: A novel mechanism for maximizing IL-7-dependent T cell survival. Immunity 2004, 21, 289–302.
20. Ouyang, W.; Oh, S.A.; Ma, Q.; Bivona, M.R.; Zhu, J.; Li, M.O. TGF-β cytokine signaling promotes CD8+ t cell development and low-affinity CD4+ T cell homeostasis by regulation of interleukin-7 receptor α expression. Immunity 2013, 39, 335–346.
21. Lundstrom, W.; Highfill, S.; Walsh, S.T.; Beq, S.; Morse, E.; Kockum, I.; Alfredsson, L.; Olsson, T.; Hillert, J.; Mackall, C.L. Soluble IL7Rα potentiates IL-7 bioactivity and promotes autoimmunity. Proc. Natl. Acad. Sci. USA 2013, 110, E1761–E1770.
22. Swainson, L.; Kinet, S.; Mongellaz, C.; Sourisseau, M.; Henriques, T.; Taylor, N. IL-7-induced proliferation of recent thymic emigrants requires activation of the PI3K pathway. Blood 2007, 109, 1034–1042.
23. Fujita, N.; Sato, S.; Katayama, K.; Tsuruo, T. Akt-dependent phosphorylation of p27kip1 promotes binding to 14-3-3 and cytoplasmic localization. J. Biol. Chem. 2002, 277, 28706–28713.
24. Barata, J.T.; Silva, A.; Brandao, J.G.; Nadler, L.M.; Cardoso, A.A.; Boussiotis, V.A. Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells. J. Exp. Med. 2004, 200, 659–669.
25. Patra, A.K.; Avots, A.; Zahedi, R.P.; Schuler, T.; Sickmann, A.; Bommhardt, U.; Serfling, E. An alternative NFAT-activation pathway mediated by IL-7 is critical for early thymocyte development. Nat. Immunol. 2013, 14, 127–135.
26. Mazzucchelli, R.; Durum, S.K. Interleukin-7 receptor expression: Intelligent design. Nat. Rev. Immunol. 2007, 7, 144–154.
27. Schlissel, M.S.; Durum, S.D.; Muegge, K. The interleukin 7 receptor is required for t cell receptor gamma locus accessibility to the V(D)J recombinase. J. Exp. Med. 2000, 191, 1045–1050.
28. Bolotin, E.; Annett, G.; Parkman, R.; Weinberg, K. Serum levels of IL-7 in bone marrow transplant recipients: Relationship to clinical characteristics and lymphocyte count. Bone Marrow Transplant. 1999, 23, 783–788.
29. Jameson, S.C. Maintaining the norm: T-cell homeostasis. Nat. Rev. Immunol. 2002, 2, 547–556.
30. Bream, J.H.; Hodge, D.L.; Gonsky, R.; Spolski, R.; Leonard, W.J.; Krebs, S.; Targan, S.; Morinobu, A.; OʼShea, J.J.; Young, H.A. A distal region in the interferon-γ gene is a site of epigenetic remodeling and transcriptional regulation by interleukin-2. J. Biol. Chem. 2004, 279, 41249–41257.
31. Kimura, M.Y.; Pobezinsky, L.A.; Guinter, T.I.; Thomas, J.; Adams, A.; Park, J.H.; Tai, X.; Singer, A. IL-7 signaling must be intermittent, not continuous, during CD8+ T cell homeostasis to promote cell survival instead of cell death. Nat. Immunol. 2013, 14, 143–151.
32. Noguchi, M.; Sarin, A.; Aman, M.J.; Nakajima, H.; Shores, E.W.; Henkart, P.A.; Leonard, W.J. Functional cleavage of the common cytokine receptor γ chain (γc) by calpain. Proc. Natl. Acad. Sci. USA 1997, 94, 11534–11539.
33. Katz, G.; Pobezinsky, L.A.; Jeurling, S.; Shinzawa, M.; van Laethem, F.; Singer, A. T cell receptor stimulation impairs IL-7 receptor signaling by inducing expression of the microrna miR-17 to target janus kinase 1. Sci. Signal. 2014, 7, doi:10.1126/scisignal.2005221.
34. Malhotra, D.; Fletcher, A.L.; Turley, S.J. Stromal and hematopoietic cells in secondary lymphoid organs: Partners in immunity. Immunol. Rev. 2013, 251, 160–176.
35. Turley, S.J.; Fletcher, A.L.; Elpek, K.G. The stromal and haematopoietic antigen-presenting cells that reside in secondary lymphoid organs. Nat. Rev. Immunol. 2010, 10, 813–825.
36. Bajenoff, M.; Egen, J.G.; Koo, L.Y.; Laugier, J.P.; Brau, F.; Glaichenhaus, N.; Germain, R.N. Stromal cell networks regulate lymphocyte entry, migration, and territoriality in lymph nodes. Immunity 2006, 25, 989–1001.
37. Zhao, L.; Liu, L.; Gao, J.; Yang, Y.; Hu, C.; Guo, B.; Zhu, B. T lymphocytes maintain structure and function of fibroblastic reticular cells via lymphotoxin (LT)-B. BMC Immunol. 2014, 15, doi:10.1186/s12865-014-0033-4.
38. Zhao, L.; Chen, J.; Liu, L.; Gao, J.; Guo, B.; Zhu, B. Essential role of TNF-α in development of spleen fibroblastic reticular cells. Cell. Immunol. 2015, 293, 130–136.
39. Anne, L.; Fletcher, D.M.; Shannon, J.T. Lymph node stroma broaden the peripheral tolerance paradigm. Trends Immunol. 2011, 32, 6.
40. Lund, A.W.; Duraes, F.V.; Hirosue, S.; Raghavan, V.R.; Nembrini, C.; Thomas, S.N.; Issa, A.; Hugues, S.; Swartz, M.A. VEGF-c promotes immune tolerance in B16 melanomas and cross-presentation of tumor antigen by lymph node lymphatics. Cell Rep. 2012, 1, 191–199.
41. Rosenberg, S.A. IL-2: The first effective immunotherapy for human cancer. J. Immunol. 2014, 192, 5451–5458.
42. Waldmann, T.A. The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: Implications for cancer therapy. Cancer Immunol. Res. 2015, 3, 219–227.
43. Zarogoulidis, P.; Lampaki, S.; Yarmus, L.; Kioumis, I.; Pitsiou, G.; Katsikogiannis, N.; Hohenforst-Schmidt, W.; Li, Q.; Huang, H.; Sakkas, A.; et al. Interleukin-7 and interleukin-15 for cancer. J. Cancer 2014, 5, 765–773.
44. Steel, J.C.; Waldmann, T.A.; Morris, J.C. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol. Sci. 2012, 33, 35–41.
45. Habibi, M.; Kmieciak, M.; Graham, L.; Morales, J.K.; Bear, H.D.; Manjili, M.H. Radiofrequency thermal ablation of breast tumors combined with intralesional administration of IL-7 and IL-15 augments anti-tumor immune responses and inhibits tumor development and metastasis. Breast Cancer Res. Treat. 2009, 114, 423–431.
46. Le, H.K.; Graham, L.; Miller, C.H.; Kmieciak, M.; Manjili, M.H.; Bear, H.D. Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2. Cancer Immunol. Immunother. 2009, 58, 1565–1576.
47. Cha, E.; Graham, L.; Manjili, M.H.; Bear, H.D. IL-7 + IL-15 are superior to IL-2 for the ex vivo expansion of 4T1 mammary carcinoma-specific T cells with greater efficacy against tumors in vivo. Breast Cancer Res. Treat. 2010, 122, 359–369.
48. Miller, P.W.; Sharma, S.; Stolina, M.; Butterfield, L.H.; Luo, J.; Lin, Y.; Dohadwala, M.; Batra, R.K.; Wu, L.; Economou, J.S.; et al. Intratumoral administration of adenoviral interleukin 7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication. Hum. Gene Ther. 2000, 11, 53–65.
49. Schroten, C.; Scheffer, R.; Boon, L.; de Ridder, C.M.; Bangma, C.H.; Kraaij, R. Tumor protection by IL-7 secreting whole cell vaccine is merely mediated by NK1.1-positive cells. J. Immunother. 2012, 35, 125–130.
50. Schroten-Loef, C.; de Ridder, C.M.; Reneman, S.; Crezee, M.; Dalgleish, A.; Todryk, S.M.; Bangma, C.H.; Kraaij, R. A prostate cancer vaccine comprising whole cells secreting IL-7, effective against subcutaneous challenge, requires local GM-CSF for intra-prostatic efficacy. Cancer Immunol. Immunother. 2009, 58, 373–381.
51. Sportes, C.; Babb, R.R.; Krumlauf, M.C.; Hakim, F.T.; Steinberg, S.M.; Chow, C.K.; Brown, M.R.; Fleisher, T.A.; Noel, P.; Maric, I.; et al. Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy. Clin. Cancer Res. 2010, 16, 727–735.
52. Rosenberg, S.A.; Sportes, C.; Ahmadzadeh, M.; Fry, T.J.; Ngo, L.T.; Schwarz, S.L.; Stetler-Stevenson, M.; Morton, K.E.; Mavroukakis, S.A.; Morre, M.; et al. IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J. Immunother. 2006, 29, 313–319.
53. Sportes, C.; Hakim, F.T.; Memon, S.A.; Zhang, H.; Chua, K.S.; Brown, M.R.; Fleisher, T.A.; Krumlauf, M.C.; Babb, R.R.; Chow, C.K.; et al. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J. Exp. Med. 2008, 205, 1701–1714.
54. Ray-Coquard, I.; Cropet, C.; van Glabbeke, M.; Sebban, C.; le Cesne, A.; Judson, I.; Tredan, O.; Verweij, J.; Biron, P.; Labidi, I.; et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 2009, 69, 5383–5391.
55. Lu, H.; Zhao, Z.; Kalina, T.; Gillespy, T., III; Liggitt, D.; Andrews, R.G.; Maloney, D.G.; Kiem, H.P.; Storek, J. Interleukin-7 improves reconstitution of antiviral CD4 T cells. Clin. Immunol. 2005, 114, 30–41.
56. Beq, S.; Rozlan, S.; Gautier, D.; Parker, R.; Mersseman, V.; Schilte, C.; Assouline, B.; Rance, I.; Lavedan, P.; Morre, M.; et al. Injection of glycosylated recombinant simian IL-7 provokes rapid and massive T-cell homing in rhesus macaques. Blood 2009, 114, 816–825.
57. Okamoto, Y.; Douek, D.C.; McFarland, R.D.; Koup, R.A. Effects of exogenous interleukin-7 on human thymus function. Blood 2002, 99, 2851–2858.
58. Colombetti, S.; Levy, F.; Chapatte, L. IL-7 adjuvant treatment enhances long-term tumor-antigenspecific CD8+ T-cell responses after immunization with recombinant lentivector. Blood 2009, 113, 6629–6637.
59. Pellegrini, M.; Calzascia, T.; Elford, A.R.; Shahinian, A.; Lin, A.E.; Dissanayake, D.; Dhanji, S.; Nguyen, L.T.; Gronski, M.A.; Morre, M.; et al. Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies. Nat. Med. 2009, 15, 528–536.
60. Zhao, L.; Mei, Y.; Sun, Q.; Guo, L.; Wu, Y.; Yu, X.; Hu, B.; Liu, X.; Liu, H. Autologous tumor vaccine modified with recombinant new castle disease virus expressing IL-7 promotes antitumor immune response. J. Immunol. 2014, 193, 735–745.
61. Yuan, C.H.; Yang, X.Q.; Zhu, C.L.; Liu, S.P.; Wang, B.C.; Wang, F.B. Interleukin-7 enhances the in vivo anti-tumor activity of tumor-reactive CD8+ T cells with induction of IFN-γ in a murine breast cancer model. Asian Pac. J. Cancer Prev. 2014, 15, 265–271.
62. Lai, L.; Jin, J.; Goldschneider, I. In vivo antitumor activity of a recombinant IL-7/HGFβ hybrid cytokine in mice. Cancer Res. 2011, 71, 61–67.
63. Cieri, N.; Camisa, B.; Cocchiarella, F.; Forcato, M.; Oliveira, G.; Provasi, E.; Bondanza, A.; Bordignon, C.; Peccatori, J.; Ciceri, F.; et al. IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood 2013, 121, 573–584.
64. Andersson, A.; Srivastava, M.K.; Harris-White, M.; Huang, M.; Zhu, L.; Elashoff, D.; Strieter, R.M.; Dubinett, S.M.; Sharma, S. Role of CXCR3 ligands in IL-7/IL-7R α-FC-mediated antitumor activity in lung cancer. Clin. Cancer Res. 2011, 17, 3660–3672.
65. Heninger, A.K.; Theil, A.; Wilhelm, C.; Petzold, C.; Huebel, N.; Kretschmer, K.; Bonifacio, E.; Monti, P. IL-7 abrogates suppressive activity of human CD4+CD25+Foxp3+ regulatory T cells and allows expansion of alloreactive and autoreactive t cells. J. Immunol. 2012, 189, 5649–5658.
66. Andersson, A.; Yang, S.C.; Huang, M.; Zhu, L.; Kar, U.K.; Batra, R.K.; Elashoff, D.; Strieter, R.M.; Dubinett, S.M.; Sharma, S. IL-7 promotes CXCR3 ligand-dependent T cell antitumor reactivity in lung cancer. J. Immunol. 2009, 182, 6951–6958.
67. Silva, A.; Laranjeira, A.B.; Martins, L.R.; Cardoso, B.A.; Demengeot, J.; Yunes, J.A.; Seddon, B.; Barata, J.T. IL-7 contributes to the progression of human T-cell acute lymphoblastic leukemias. Cancer Res. 2011, 71, 4780–4789.
68. Barata, J.T.; Cardoso, A.A.; Boussiotis, V.A. Interleukin-7 in T-cell acute lymphoblastic leukemia: An extrinsic factor supporting leukemogenesis? Leukemia Lymphoma 2005, 46, 483–495.
69. Cattaruzza, L.; Gloghini, A.; Olivo, K.; di Francia, R.; Lorenzon, D.; de Filippi, R.; Carbone, A.; Colombatti, A.; Pinto, A.; Aldinucci, D. Functional coexpression of interleukin (IL)-7 and its receptor (IL-7R) on hodgkin and reed-sternberg cells: Involvement of IL-7 in tumor cell growth and microenvironmental interactions of Hodgkinʼs lymphoma. Int. J. Cancer 2009, 125, 1092–1101.
70. Yamanaka, K.; Clark, R.; Rich, B.; Dowgiert, R.; Hirahara, K.; Hurwitz, D.; Shibata, M.; Mirchandani, N.; Jones, D.A.; Goddard, D.S.; et al. Skin-derived interleukin-7 contributes to the proliferation of lymphocytes in cutaneous T-cell lymphoma. Blood 2006, 107, 2440–2445.
71. Al-Rawi, M.A.; Mansel, R.E.; Jiang, W.G. Interleukin-7 (IL-7) and IL-7 receptor (IL-7R) signalling complex in human solid tumours. Histol. Histopathol. 2003, 18, 911–923.
72. Roato, I.; D’Amelio, P.; Gorassini, E.; Grimaldi, A.; Bonello, L.; Fiori, C.; Delsedime, L.; Tizzani, A.; Libero, A.D.; Isaia, G.; et al. Osteoclasts are active in bone forming metastases of prostate cancer patients. PLoS ONE 2008, 3, e3627.
73. Mengus, C.; le Magnen, C.; Trella, E.; Yousef, K.; Bubendorf, L.; Provenzano, M.; Bachmann, A.; Heberer, M.; Spagnoli, G.C.; Wyler, S. Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer. J. Transl. Med. 2011, 9, doi:10.1186/1479-5876-9-162.
74. Schroten, C.; Dits, N.F.; Steyerberg, E.W.; Kranse, R.; van Leenders, A.G.; Bangma, C.H.; Kraaij, R. The additional value of TGFβ1 and IL-7 to predict the course of prostate cancer progression. Cancer Immunol. Immunother. 2012, 61, 905–910.
75. Lambeck, A.J.; Crijns, A.P.; Leffers, N.; Sluiter, W.J.; ten Hoor, K.A.; Braid, M.; van der Zee, A.G.; Daemen, T.; Nijman, H.W.; Kast, W.M. Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: A potential role for interleukin 7. Clin. Cancer Res. 2007, 13, 2385–2391.
76. Roato, I.; Caldo, D.; Godio, L.; DʼAmico, L.; Giannoni, P.; Morello, E.; Quarto, R.; Molfetta, L.; Buracco, P.; Mussa, A.; et al. Bone invading NSCLC cells produce IL-7: Mice model and human histologic data. BMC Cancer 2010, 10, doi:10.1186/1471-2407-10-12.
77. Cosenza, L.; Gorgun, G.; Urbano, A.; Foss, F. Interleukin-7 receptor expression and activation in nonhaematopoietic neoplastic cell lines. Cell Signal. 2002, 14, 317–325.
78. Suzuki, K.; Kadota, K.; Sima, C.S.; Nitadori, J.; Rusch, V.W.; Travis, W.D.; Sadelain, M.; Adusumilli, P.S. Clinical impact of immune microenvironment in stage I lung adenocarcinoma: Tumor interleukin-12 receptor β2 (IL-12Rβ2), IL-7R, and stromal Foxp3/CD3 ratio are independent predictors of recurrence. J. Clin. Oncol. 2013, 31, 490–498.
79. Capitini, C.M.; Chisti, A.A.; Mackall, C.L. Modulating t-cell homeostasis with IL-7: Preclinical and clinical studies. J. Intern. Med. 2009, 266, 141–153.